

ABSTRACT**DRUG UTILIZATION STUDY OF ANTITUBERCULOSIS
IN PULMONARY TUBERCULOSIS PATIENT WITH LIVER
DISEASE****(The Study at Ambulatory Unit of TB RSUD Dr. Soetomo Surabaya)**

SARI RISANTI

Tuberculosis (TB) is infectious disease caused by *Mycobacterium tuberculosis*. In patients with liver disease, the antituberculosis drug regimen use will be different. WHO and Kemenkes RI have recommended management therapy for this condition. Therefore, this study was needed to review antituberculosis profile in pulmonary tuberculosis patient with liver disease and identify the drug related problem of tuberculosis therapy. It was a retrospective study during period 01 Januari 2014 until 31 December 2016. The sample was medical records of adult tuberculosis pulmonary patient (18-65 years old) receiving antituberculosis with liver disease (N=30).

The results showed that 30 patients had drug induced hepatitis (DIH) due to antituberculosis and 3 patient had a history of other liver disease. The most initial regimens given were SEO (streptomycin, ethambutol, and ofloxacin) (33.3%). Those were combinations of antituberculosis non hepatotoxic that recommended by WHO for TB-DIH. The most final regimens were RHE (rifampicin, isoniazid, and ethambutol) (56.7%). Those were combinations of two antituberculosis non hepatotoxic that recommended by WHO if the patient's liver condition improved. The route and frequency of administration had been appropriated. While in dose regimentation, some patients get a less appropriated dose. After obtaining the regimen therapy, the patient's liver condition improved and 7 patients (23.3%) were recovered and 6 patients (20%) were complete treatment. Identification of drug related problem that found were actual adverse drug reaction and potential drug interactions. The most actual adverse drug reaction were nausea (53.3%) and the most potential drug interactions were antituberculosis drugs with ranitidine (13.3%).

Based on the explanation above, TB patients with DIH require a right consideration regarding the combinations of antituberculosis drugs. Therefore, a good collaboration between doctor and pharmacist is needed.

Keywords : Antituberculosis, liver disease, DIH, drug related problem.